BI-3802
Based on 3 publication(s) in Google Scholar
BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
- 純度 : 99.27%
- CAS 番号: 2166387-65-9
- 分子式: C24H29ClN6O3
- 分子量:484.98
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-111381
BI-3812Bcl-2 Family Inhibitor -
HY-158105
ARV-393BCL6 PROTAC Degrader -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-102027
FX1BCL6 Inhibitor -
HY-172736
ToviblidegBCL6 Degrader -
HY-100741
S63845MCL1 Inhibitor -
HY-146185
CCT373566BCL6 Molecular Glue Degrader -
HY-15141
StaurosporinePKC/PKA Inhibitor -
HY-10087
NavitoclaxBcl-2 Inhibitor -
HY-10984
PomalidomideImmunomodulatory Agent -
HY-10219
RapamycinmTOR Inhibitor -
HY-12163
EntinostatHDAC Class I Inhibitor
MedChemExpress（MCE）の使用を引用している文献 BI-3802
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
生物活性
製品説明
IC50 & Target
IC50: ≤ 3 nM (BCL6 BTB)[1]
体外実験
化学情報
-
CAS 番号 2166387-65-9
-
性状 Solid
-
分子量 484.98
-
分子式 C24H29ClN6O3
-
Color White to off-white
-
SMILES
ClC1=CN=C(N2C[C@H](C)C[C@H](C)C2)N=C1NC3=CC(C=C(OCC(NC)=O)C(N4C)=O)=C4C=C3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Genome Biol
2025 Sep 2;26(1):264. PMID: 40898359
BI-3802 purchased from MedChemExpress. Usage Cited in: Genome Biol. 2025 Sep 2;26(1):264. [Abstract]
Terminal cumulative MSD of NONO-GFP foci at final time point. Each circle indicates a single NONO-GFP focus. For untransfected groups, 45 foci were analyzed from 10 cells; for + BI-3802, 38 from 15 cells; and for + BI-3812, 37 foci from 15 cells across three biological replicates.
BI-3802 purchased from MedChemExpress. Usage Cited in: Genome Biol. 2025 Sep 2;26(1):264. [Abstract]
Compared to cells untransfected with the inducible HP1α switch, both the length of trajectories and terminal MSD of NONO-GFP foci were increased by the promoted condensation of HP1α using BI-3802 (1 μM).
-
bioRxiv
2025 Mar 17:2025.03.14.643353. PMID: 40166278
溶剤 & 溶解度
体外:
DMSO : 6.67 mg/mL (13.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0619 mL | 10.3097 mL | 20.6194 mL | 51.5485 mL |
| 5 mM | 0.4124 mL | 2.0619 mL | 4.1239 mL | 10.3097 mL | |
| 10 mM | 0.2062 mL | 1.0310 mL | 2.0619 mL | 5.1549 mL |
BI-3802 関連分類
HY-108705 関連分類
Powered by Bioz